New study to track how risdiplam helps kids with spinal muscle atrophy in daily life

NCT ID NCT07531719

First seen Apr 24, 2026 · Last updated Jun 20, 2026 · Updated 13 times

Summary

This study will follow 30 children with Type I or Type II spinal muscle atrophy who are taking risdiplam. Researchers will track their motor skills and safety over 24 months using standard tests. The goal is to see how well the drug works in real-world settings, not just in controlled trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SPINAL MUSCULAR ATROPHY TYPE I are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

risdiplam

What this could lead to

If successful, this study could provide real-world evidence on how well risdiplam improves motor function in children with spinal muscle atrophy.

What could go wrong

This is an observational study, not a controlled trial, so results may be less definitive. It is also small (30 participants) and has not yet started recruiting.

Conditions

The condition(s) this trial relates to.

spinal muscular atrophy spinal muscular atrophy, type 1 spinal muscular atrophy, type II

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.